<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235962</url>
  </required_header>
  <id_info>
    <org_study_id>113387</org_study_id>
    <secondary_id>2010-020965-26</secondary_id>
    <secondary_id>CPZP034D2301</secondary_id>
    <nct_id>NCT01235962</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized Phase III study is to evaluate whether pazopanib compared with placebo can&#xD;
      prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of&#xD;
      developing recurrence after undergoing kidney cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this ongoing study was to evaluate DFS with pazopanib 600 mg daily&#xD;
      initial dose as compared with placebo as adjuvant therapy for subjects with localized/locally&#xD;
      advanced RCC following nephrectomy.&#xD;
&#xD;
      Subjects with locally recurrent renal cell carcinoma (RCC), bilateral RCC, or history of&#xD;
      another malignancy were excluded from enrolling in the study.&#xD;
&#xD;
      The study was comprised of three successive study periods: 1) the Screening/Baseline period,&#xD;
      2) the study treatment period, and 3) the DFS /OS follow-up period. The Screening/Baseline&#xD;
      period had a maximum duration of 12 weeks from the date of nephrectomy to the date of&#xD;
      randomization.&#xD;
&#xD;
      After a subject met all the eligibility criteria and completed all the required baseline&#xD;
      assessments, the subject was randomized in a 1:1 ratio to receive once daily blinded&#xD;
      treatment with either pazopanib 600 mg as initial dose or matching placebo based on&#xD;
      pre-defined stratification factors.&#xD;
&#xD;
      Subjects received continuous daily treatment until completion of the 12-month treatment&#xD;
      period, disease recurrence, or unacceptable toxicity/intolerance. Subsequent adjuvant&#xD;
      therapies for RCC were not allowed. During the study treatment and DFS follow-up periods,&#xD;
      subjects received routine safety and efficacy assessments.&#xD;
&#xD;
      The study treatment period was 12 months. Subjects received continuous daily treatment until&#xD;
      completion of the 12 month treatment period, disease recurrence, or unacceptable&#xD;
      toxicity/intolerance. Subsequent adjuvant therapies for RCC were not allowed.&#xD;
&#xD;
      All subjects, regardless of study treatment status (i.e. premature discontinuation or&#xD;
      completion of the 12-month treatment), were to be followed with routine imaging assessments&#xD;
      and remain blinded until objective evidence of disease recurrence was obtained or until the&#xD;
      study achieved the required number of events for the primary endpoint of DFS (319 events).&#xD;
      After objective evidence of disease recurrence was obtained, subjects could be unblinded and&#xD;
      received the first-line treatment for metastatic RCC per local standard of care.&#xD;
&#xD;
      All subjects were off treatment for at least 4 years at the end of study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2010</start_date>
  <completion_date type="Actual">April 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo</measure>
    <time_frame>approximately 5 years</time_frame>
    <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo</measure>
    <time_frame>approximately 8.5 years</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who did not die, time to death was censored at the last date of known contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS Rates at Yearly Time Points With Pazopanib 600 mg Daily Initial Dose vs. Placebo</measure>
    <time_frame>yearly for 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS With Pazopanib vs. Placebo</measure>
    <time_frame>approximately 5 years</time_frame>
    <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS With Pazopanib vs. Placebo</measure>
    <time_frame>approximately 8.5 years</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who do not die, time to death will be censored at the last date of known contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS Rates at Yearly Time Points With Pazopanib vs. Placebo</measure>
    <time_frame>yearly for 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS Pazopanib 800 mg Daily Initial Dose vs. Placebo</measure>
    <time_frame>approximately 5 years</time_frame>
    <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS With Pazopanib 800 mg Daily Initial Dose vs. Placebo</measure>
    <time_frame>approximately 8.5 years</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who did not die, time to death was censored at the last date of known contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/Functional Assessment of Cancer Therapy-Kidney Symptom Index -19 (FACT FKSI-19) Total Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (FKSI-DRS-P, FKSI-DRS-E, FKSI-TSE, FKSI-FWB) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition. DFS: disease-free survival; FU: follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Disease-related Symptoms-physical (DRS-P) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-P domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to 12 questions (&quot;I have a lack of energy,&quot; &quot;I feel pain,&quot; for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 48). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Disease Related Symptoms-emotional (DRS-E) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU,48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-E domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to the question of &quot;I worry that my condition will get worse&quot; by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 4). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Treatment Side Effects (TSE) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU,48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The TSE domain assesses side effects experienced in the past 7 days. Participants are asked to respond to 3 questions (&quot;I have nausea,&quot; &quot;I have diarrhea,&quot; and &quot;I am bothered by side effects of treatment&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Functional Well Being (FWB) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU,48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The FWB domain assesses well being in the past 7 days. Participants are asked to respond to 3 questions (&quot;I am able to work,&quot; &quot;I am able to enjoy life,&quot; and &quot;I am content with the quality of my life now&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using EuroQoL-5D (EQ-5D) Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life measured by EQ-5D thermometer (thermo) score and EQ-5D utility index (UI) score. The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Total Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (FKSI-DRS-P, FKSI-DRS-E, FKSI-TSE, FKSI-FWB) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition. DFS: disease-free survival; FU: follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Disease-related Symptoms-physical (DRS-P) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-P domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to 12 questions (&quot;I have a lack of energy,&quot; &quot;I feel pain,&quot; for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 48). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Disease-related Symptoms-emotional (DRS-E) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-E domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to the question of &quot;I worry that my condition will get worse&quot; by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 4).A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Treatment Side Effects (TSE) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The TSE domain assesses side effects experienced in the past 7 days. Participants are asked to respond to 3 questions (&quot;I have nausea,&quot; &quot;I have diarrhea,&quot; and &quot;I am bothered by side effects of treatment&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Functional Well Being (FWB) Domain Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The FWB domain assesses well being in the past 7 days. Participants are asked to respond to 3 questions (&quot;I am able to work,&quot; &quot;I am able to enjoy life,&quot; and &quot;I am content with the quality of my life now&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using EuroQoL-5D (EQ-5D) Score</measure>
    <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
    <description>Health outcome and quality of life measured by using EQ-5D thermometer score and EQ-5D utility index (UI) score. The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1538</enrollment>
  <condition>Renal Cell Carcinoma (RCC)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.</description>
    <arm_group_label>pazopanib</arm_group_label>
    <other_name>PZP034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.</description>
    <arm_group_label>pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Diagnosis of RCC with clear-cell or predominant clear-cell histology&#xD;
&#xD;
          -  Subjects with non-metastatic disease (M0) fulfilling any of the following combinations&#xD;
             of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging&#xD;
             version 2010 and Fuhrman nuclear grading.&#xD;
&#xD;
               -  pT2, G3 or G4, N0; or,&#xD;
&#xD;
               -  pT3, G any, N0; or,&#xD;
&#xD;
               -  pT4, G any, N0; or,&#xD;
&#xD;
               -  pT any, G any, N1&#xD;
&#xD;
          -  Fulfill all of the following criteria of disease-free status at baseline:&#xD;
&#xD;
               -  Had complete gross surgical resection of all RCC via radical or partial&#xD;
                  nephrectomy using either open or laparoscopic technique.&#xD;
&#xD;
               -  Baseline imaging of chest, abdomen and pelvis shows no metastasis or residual&#xD;
                  tumor lesions as confirmed centrally by an independent radiologist.&#xD;
&#xD;
          -  Received no prior adjuvant or neo-adjuvant treatment for RCC&#xD;
&#xD;
          -  Recovered from nephrectomy: any surgery related toxicities should be reduced to ≤&#xD;
             grade 1 per NCI Common Terminology Criteria for Adverse Events (CTCAE) (Version 4)&#xD;
&#xD;
          -  Karnofsky performance scale (KPS) of ≥ 80&#xD;
&#xD;
          -  Adequate organ system function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another malignancy. Exception: Subjects who have had another malignancy and&#xD;
             have been disease-free for 5 years, or subjects with a history of completely resected&#xD;
             non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding including, but not limited to:&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other&#xD;
                  gastrointestinal conditions with increased risk of perforation&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment&#xD;
&#xD;
          -  Active diarrhea of any grade&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may affect absorption of&#xD;
             investigational product including, but not limited to:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Major resection of the stomach or small bowel&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  History of active hepatitis&#xD;
&#xD;
          -  Presence of uncontrolled infection.&#xD;
&#xD;
          -  History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Coronary artery bypass graft surgery&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  History of Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
             Association Classification of Congestive Heart Failure&#xD;
&#xD;
          -  History of cerebrovascular accident including transient ischemic attack (TIA),&#xD;
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.&#xD;
&#xD;
          -  Corrected QT interval (QTc) &gt; 480 milliseconds (msec)&#xD;
&#xD;
          -  Poorly controlled hypertension, defined as systolic blood pressure (SBP) of ≥140 mmHg&#xD;
             or diastolic blood pressure (DBP) of ≥ 90mmHg.&#xD;
&#xD;
        Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to&#xD;
        study entry. Blood pressure (BP) must be re-assessed on two occasions that are separated by&#xD;
        a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values&#xD;
        from each BP assessment must be &lt;140/90 mmHg in order for a subject to be eligible for the&#xD;
        study (see Section 7.6.2 for instruction on blood pressure measurement and obtaining mean&#xD;
        blood pressure values).&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
             could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
             study procedures&#xD;
&#xD;
          -  Unable or unwilling to discontinue use of prohibited medications for at least 14 days&#xD;
             or five half-lives of a drug (whichever is longer) prior to the first dose of study&#xD;
             treatment and for the duration of the study.&#xD;
&#xD;
          -  Concurrent therapy given to treat cancer including treatment with an investigational&#xD;
             agent or concurrent participation in another clinical trial involving anti-cancer&#xD;
             investigational drug.&#xD;
&#xD;
          -  Administration of an investigational drug within 30 days or 5 half-lives, whichever is&#xD;
             longer, preceding the first dose of study treatment.&#xD;
&#xD;
          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to pazopanib or excipients that in the opinion of the investigator&#xD;
             contraindicates their participation.&#xD;
&#xD;
          -  Prior or current use of systemic anti-VEGF inhibitors, cytokines (e.g. interferon,&#xD;
             interleukin 2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antioch</city>
        <state>California</state>
        <zip>94531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-0750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>B1880BBF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Aut6noma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1050AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdova</state>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdova</state>
        <zip>X5006HBF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cipolletti</city>
        <state>Río Negro</state>
        <zip>R8324EMB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ijui</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20 551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaíso</state>
        <zip>254-0364</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 Aarhus C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dk-2730 Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>ANGERS Cedex 2</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tours Cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kirchheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sigmaringen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerth</city>
        <state>Bayern</state>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weiden</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunschweig</city>
        <state>Niedersachsen</state>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goslar</city>
        <state>Niedersachsen</state>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergisch Gladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moenchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Velbert</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dessau</city>
        <state>Sachsen-Anhalt</state>
        <zip>06846</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eisleben</city>
        <state>Sachsen-Anhalt</state>
        <zip>06295</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plauen</city>
        <state>Sachsen</state>
        <zip>08523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23566</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallaght, Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola (FC)</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano (MI)</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Candiolo (TO)</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terni</city>
        <state>Umbria</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Negrar</city>
        <state>Veneto</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goyang-si, Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seongnam-si Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songpa-gu, Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Konin</city>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-108</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavropol</city>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ufa,</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 66</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dos Hermanas (Sevilla)</city>
        <zip>41700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cornwall</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Luxembourg</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.</citation>
    <PMID>20100962</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2010</study_first_posted>
  <results_first_submitted>April 15, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <disposition_first_submitted>January 26, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 27, 2017</disposition_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-angiogenic agent</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>pazopanib</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>VEGFR inhibitor</keyword>
  <keyword>localized or locally</keyword>
  <keyword>advanced renal cell carcinoma (RCC) following nephrectomy</keyword>
  <keyword>advanced RCC</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was planned to include 1500 subjects. A total of 1538 subjects were enrolled and analyzed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ITT Pazopanib 800 mg</title>
          <description>Pazopanib 800 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
        </group>
        <group group_id="P2">
          <title>ITT Placebo 800 mg</title>
          <description>Placebo matching pazopanib 800 mg daily. Complete treatment is 12 months.</description>
        </group>
        <group group_id="P3">
          <title>ITT Pazopanib 600 mg</title>
          <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
        </group>
        <group group_id="P4">
          <title>ITT Placebo 600 mg</title>
          <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="571"/>
                <participants group_id="P4" count="564"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Prem. Withdrawn = Did Not Complete Study</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Deaths</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="453"/>
                <participants group_id="P4" count="478"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="86"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT 800 included all randomized subjects with a scheduled initial dose of 800 mg daily.&#xD;
ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.&#xD;
Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
      <group_list>
        <group group_id="B1">
          <title>ITT Pazopanib 800 mg</title>
          <description>Pazopanib 800 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
        </group>
        <group group_id="B2">
          <title>ITT Placebo 800 mg</title>
          <description>Placebo matching pazopanib 800 mg daily. Complete treatment is 12 months.</description>
        </group>
        <group group_id="B3">
          <title>ITT Pazopanib 600 mg</title>
          <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
        </group>
        <group group_id="B4">
          <title>ITT Placebo 600 mg</title>
          <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="571"/>
            <count group_id="B4" value="564"/>
            <count group_id="B5" value="1538"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>=&gt;18 to &lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="430"/>
                    <measurement group_id="B4" value="406"/>
                    <measurement group_id="B5" value="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;65 to &lt;75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;75 to &lt;85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="164"/>
                    <measurement group_id="B5" value="447"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="398"/>
                    <measurement group_id="B4" value="400"/>
                    <measurement group_id="B5" value="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="471"/>
                    <measurement group_id="B4" value="481"/>
                    <measurement group_id="B5" value="1298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo</title>
        <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
        <time_frame>approximately 5 years</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo</title>
          <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = DFS median and confidence interval were not determined because not enough events occurred at the analysis</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = DFS median and confidence interval were not determined because not enough events occurred at the analysis</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1649</p_value>
            <method>Stratified Log-Rank</method>
            <param_type>Adjusted Hazard Ratio</param_type>
            <param_value>0.862</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.699</ci_lower_limit>
            <ci_upper_limit>1.063</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who did not die, time to death was censored at the last date of known contact.</description>
        <time_frame>approximately 8.5 years</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who did not die, time to death was censored at the last date of known contact.</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="NA" upper_limit="NA">NA = the last follow-up patient in this group died at the end of study, so the median survival was estimated (the survival curve crossed 50%). But the 95% CI was not estimable due to less than 50% events (death) occurring in pazopanib group.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = the last follow-up patient in this group was censored at the end of study and less than 50% events (death) occurred, so both median and 95%CI were not estimable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9880</p_value>
            <method>Stratified Log-Rank</method>
            <param_type>Adjusted Hazard Ratio</param_type>
            <param_value>0.998</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.759</ci_lower_limit>
            <ci_upper_limit>1.311</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DFS Rates at Yearly Time Points With Pazopanib 600 mg Daily Initial Dose vs. Placebo</title>
        <time_frame>yearly for 4 years</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rates at Yearly Time Points With Pazopanib 600 mg Daily Initial Dose vs. Placebo</title>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DFS at 1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.81" upper_limit="0.88"/>
                    <measurement group_id="O2" value="0.76" lower_limit="0.72" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DFS at 2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.67" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.64" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DFS at 3 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.61" upper_limit="0.70"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.59" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DFS at 4 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DFS With Pazopanib vs. Placebo</title>
        <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
        <time_frame>approximately 5 years</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS With Pazopanib vs. Placebo</title>
          <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = DFS median or confidence interval were not determined because not enough events occurred at the analysis.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="48.1" upper_limit="NA">NA = DFS median or upper limit of confidence interval were not determined because not enough events occurred at the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0126</p_value>
            <method>Stratified Log-Rank</method>
            <param_type>Adjusted Hazard Ratio</param_type>
            <param_value>0.802</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.675</ci_lower_limit>
            <ci_upper_limit>0.954</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS With Pazopanib vs. Placebo</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who do not die, time to death will be censored at the last date of known contact.</description>
        <time_frame>approximately 8.5 years</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>OS With Pazopanib vs. Placebo</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who do not die, time to death will be censored at the last date of known contact.</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = OS median or confidence interval were not determined because not enough events occurred at the analysis.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = OS median or confidence interval were not determined because not enough events occurred at the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9959</p_value>
            <method>Stratified Log-Rank</method>
            <param_type>Adjusted Hazard Ratio</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.796</ci_lower_limit>
            <ci_upper_limit>1.257</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DFS Rates at Yearly Time Points With Pazopanib vs. Placebo</title>
        <time_frame>yearly for 4 years</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rates at Yearly Time Points With Pazopanib vs. Placebo</title>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DFS at 1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="538"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.82" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.72" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DFS at 2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.68" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.66" lower_limit="0.63" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DFS at 3 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.62" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.58" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DFS at 4 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.58" upper_limit="0.66"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.51" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DFS Pazopanib 800 mg Daily Initial Dose vs. Placebo</title>
        <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
        <time_frame>approximately 5 years</time_frame>
        <population>ITT 800 included all randomized subjects with a scheduled initial dose of 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 800 mg</title>
            <description>Pazopanib 800 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 800 mg</title>
            <description>Placebo matching pazopanib 800 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Pazopanib 800 mg Daily Initial Dose vs. Placebo</title>
          <description>DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.</description>
          <population>ITT 800 included all randomized subjects with a scheduled initial dose of 800 mg daily.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = DFS median or confidence interval were not determined because not enough events occurred at the analysis.</measurement>
                    <measurement group_id="O2" value="48.1" lower_limit="30.1" upper_limit="NA">NA = DFS median or upper limit confidence interval were not determined because not enough events occurred at the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>Stratified Log-Rank</method>
            <param_type>Adjusted Hazard Ratio</param_type>
            <param_value>0.693</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.510</ci_lower_limit>
            <ci_upper_limit>0.943</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS With Pazopanib 800 mg Daily Initial Dose vs. Placebo</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who did not die, time to death was censored at the last date of known contact.</description>
        <time_frame>approximately 8.5 years</time_frame>
        <population>ITT 800 included all randomized subjects with a scheduled initial dose of 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 800 mg</title>
            <description>Pazopanib 800 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 800 mg</title>
            <description>Placebo matching pazopanib 800 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>OS With Pazopanib 800 mg Daily Initial Dose vs. Placebo</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.&#xD;
For subjects who did not die, time to death was censored at the last date of known contact.</description>
          <population>ITT 800 included all randomized subjects with a scheduled initial dose of 800 mg daily.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = OS was not determined because not enough events occurred at the analysis.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = OS was not determined because not enough events occurred at the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9865</p_value>
            <method>Stratified Log-Rank</method>
            <param_type>Adjusted Hazard Ratio</param_type>
            <param_value>1.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.662</ci_lower_limit>
            <ci_upper_limit>1.521</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/Functional Assessment of Cancer Therapy-Kidney Symptom Index -19 (FACT FKSI-19) Total Score</title>
        <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (FKSI-DRS-P, FKSI-DRS-E, FKSI-TSE, FKSI-FWB) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition. DFS: disease-free survival; FU: follow up</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/Functional Assessment of Cancer Therapy-Kidney Symptom Index -19 (FACT FKSI-19) Total Score</title>
          <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (FKSI-DRS-P, FKSI-DRS-E, FKSI-TSE, FKSI-FWB) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition. DFS: disease-free survival; FU: follow up</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" spread="0.452"/>
                    <measurement group_id="O2" value="-0.43" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.419"/>
                    <measurement group_id="O2" value="0.23" spread="0.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.454"/>
                    <measurement group_id="O2" value="-0.26" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.526"/>
                    <measurement group_id="O2" value="0.22" spread="0.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.653"/>
                    <measurement group_id="O2" value="0.26" spread="0.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-3.397</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.486</ci_lower_limit>
            <ci_upper_limit>-2.307</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.930</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU)</param_type>
            <param_value>-0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.003</ci_lower_limit>
            <ci_upper_limit>0.917</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.828</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.119</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.958</ci_lower_limit>
            <ci_upper_limit>1.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>-0.347</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.658</ci_lower_limit>
            <ci_upper_limit>0.964</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.841</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>-0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.843</ci_lower_limit>
            <ci_upper_limit>1.503</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Disease-related Symptoms-physical (DRS-P) Domain Score</title>
        <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-P domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to 12 questions (&quot;I have a lack of energy,&quot; &quot;I feel pain,&quot; for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 48). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Disease-related Symptoms-physical (DRS-P) Domain Score</title>
          <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-P domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to 12 questions (&quot;I have a lack of energy,&quot; &quot;I feel pain,&quot; for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 48). A negative mean indicates a worsening of condition.</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="406"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="0.278"/>
                    <measurement group_id="O2" value="-0.44" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="340"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.273"/>
                    <measurement group_id="O2" value="-0.20" spread="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                    <count group_id="O2" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.291"/>
                    <measurement group_id="O2" value="-0.53" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.332"/>
                    <measurement group_id="O2" value="-0.46" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.449"/>
                    <measurement group_id="O2" value="-0.55" spread="0.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-1.619</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.283</ci_lower_limit>
            <ci_upper_limit>-0.955</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.726</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24 M DFS FU)</param_type>
            <param_value>-0.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.750</ci_lower_limit>
            <ci_upper_limit>0.522</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.801</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36 M DFS FU)</param_type>
            <param_value>-0.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.789</ci_lower_limit>
            <ci_upper_limit>0.609</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.617</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Meat Difference (48 M DFS FU)</param_type>
            <param_value>-0.212</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.044</ci_lower_limit>
            <ci_upper_limit>0.320</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.565</p_value>
            <method>adjusted for baseline score using mixedm</method>
            <param_type>Mean Difference (54 M DFS FU)</param_type>
            <param_value>0.341</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.828</ci_lower_limit>
            <ci_upper_limit>1.510</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Disease Related Symptoms-emotional (DRS-E) Domain Score</title>
        <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-E domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to the question of &quot;I worry that my condition will get worse&quot; by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 4). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU,48M DFS FU, 54M DFS FU</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Disease Related Symptoms-emotional (DRS-E) Domain Score</title>
          <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-E domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to the question of &quot;I worry that my condition will get worse&quot; by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 4). A negative mean indicates a worsening of condition.</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.054"/>
                    <measurement group_id="O2" value="0.09" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.056"/>
                    <measurement group_id="O2" value="0.16" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="296"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.059"/>
                    <measurement group_id="O2" value="0.12" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.075"/>
                    <measurement group_id="O2" value="0.20" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.090"/>
                    <measurement group_id="O2" value="0.24" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.238</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-0.077</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.205</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.442</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU)</param_type>
            <param_value>-0.052</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.185</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.819</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.125</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.223</p_value>
            <method>analysis of covariance</method>
            <method_desc>analysis of covariance adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>-0.119</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.311</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>-0.203</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.435</ci_lower_limit>
            <ci_upper_limit>0.028</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Treatment Side Effects (TSE) Domain Score</title>
        <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The TSE domain assesses side effects experienced in the past 7 days. Participants are asked to respond to 3 questions (&quot;I have nausea,&quot; &quot;I have diarrhea,&quot; and &quot;I am bothered by side effects of treatment&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU,48M DFS FU, 54M DFS FU</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Treatment Side Effects (TSE) Domain Score</title>
          <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The TSE domain assesses side effects experienced in the past 7 days. Participants are asked to respond to 3 questions (&quot;I have nausea,&quot; &quot;I have diarrhea,&quot; and &quot;I am bothered by side effects of treatment&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="0.101"/>
                    <measurement group_id="O2" value="-0.34" spread="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.061"/>
                    <measurement group_id="O2" value="0.01" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.067"/>
                    <measurement group_id="O2" value="-00.3" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.087"/>
                    <measurement group_id="O2" value="-0.01" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.089"/>
                    <measurement group_id="O2" value="0.09" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-1.394</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.660</ci_lower_limit>
            <ci_upper_limit>-1.129</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean difference (24M DFS FU)</param_type>
            <param_value>0.117</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.307</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.081</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.074</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.796</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>-0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.249</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-models</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.237</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Functional Well Being (FWB) Domain Score</title>
        <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The FWB domain assesses well being in the past 7 days. Participants are asked to respond to 3 questions (&quot;I am able to work,&quot; &quot;I am able to enjoy life,&quot; and &quot;I am content with the quality of my life now&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU,48M DFS FU, 54M DFS FU</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using NCCN/FACT FKSI-19 Scale Functional Well Being (FWB) Domain Score</title>
          <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The FWB domain assesses well being in the past 7 days. Participants are asked to respond to 3 questions (&quot;I am able to work,&quot; &quot;I am able to enjoy life,&quot; and &quot;I am content with the quality of my life now&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="406"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.153"/>
                    <measurement group_id="O2" value="0.33" spread="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.168"/>
                    <measurement group_id="O2" value="0.32" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.177"/>
                    <measurement group_id="O2" value="0.24" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.219"/>
                    <measurement group_id="O2" value="0.42" spread="0.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.308"/>
                    <measurement group_id="O2" value="0.59" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Differencec (Week 52)</param_type>
            <param_value>-0.270</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.633</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.736</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU)</param_type>
            <param_value>0.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.336</ci_lower_limit>
            <ci_upper_limit>0.475</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.397</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.188</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.247</ci_lower_limit>
            <ci_upper_limit>0.623</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.781</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>0.081</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.488</ci_lower_limit>
            <ci_upper_limit>0.649</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>-0.278</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.094</ci_lower_limit>
            <ci_upper_limit>0.539</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using EuroQoL-5D (EQ-5D) Score</title>
        <description>Health outcome and quality of life measured by EQ-5D thermometer (thermo) score and EQ-5D utility index (UI) score. The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>ITT Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib 600 mg Daily Initial Dose vs. Placebo Assessed Using EuroQoL-5D (EQ-5D) Score</title>
          <description>Health outcome and quality of life measured by EQ-5D thermometer (thermo) score and EQ-5D utility index (UI) score. The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>ITT 600 included all randomized subjects with a scheduled initial dose of 600 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 thermo. score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.713" spread="0.858"/>
                    <measurement group_id="O2" value="1.430" spread="0.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU thermo. score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.356" spread="0.882"/>
                    <measurement group_id="O2" value="3.641" spread="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU thermo. score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.640" spread="0.882"/>
                    <measurement group_id="O2" value="2.459" spread="0.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU thermo. score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.909" spread="1.014"/>
                    <measurement group_id="O2" value="3.184" spread="1.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU thermo. score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.076" spread="1.607"/>
                    <measurement group_id="O2" value="1.053" spread="1.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.009"/>
                    <measurement group_id="O2" value="-0.001" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.010"/>
                    <measurement group_id="O2" value="0.016" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.011"/>
                    <measurement group_id="O2" value="-0.008" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.013"/>
                    <measurement group_id="O2" value="0.008" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.017"/>
                    <measurement group_id="O2" value="-0.013" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52 thermo)</param_type>
            <param_value>-0.717</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.751</ci_lower_limit>
            <ci_upper_limit>1.318</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.788</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU- thermo)</param_type>
            <param_value>-0.285</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.358</ci_lower_limit>
            <ci_upper_limit>1.788</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.266</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU- thermo)</param_type>
            <param_value>1.180</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.901</ci_lower_limit>
            <ci_upper_limit>3.262</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.570</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU - thermo)</param_type>
            <param_value>0.725</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.779</ci_lower_limit>
            <ci_upper_limit>3.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.346</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU - thermo)</param_type>
            <param_value>2.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.205</ci_lower_limit>
            <ci_upper_limit>6.251</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52 - UI)</param_type>
            <param_value>-0.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.004</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU - UI)</param_type>
            <param_value>-0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU - UI)</param_type>
            <param_value>0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.580</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU - UI)</param_type>
            <param_value>-0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.043</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.473</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU - UI)</param_type>
            <param_value>0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Total Score</title>
        <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (FKSI-DRS-P, FKSI-DRS-E, FKSI-TSE, FKSI-FWB) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition. DFS: disease-free survival; FU: follow up</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Total Score</title>
          <description>Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (FKSI-DRS-P, FKSI-DRS-E, FKSI-TSE, FKSI-FWB) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition. DFS: disease-free survival; FU: follow up</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="575"/>
                    <count group_id="O2" value="554"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.01" spread="0.385"/>
                    <measurement group_id="O2" value="-0.47" spread="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="462"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.361"/>
                    <measurement group_id="O2" value="0.33" spread="0.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.385"/>
                    <measurement group_id="O2" value="-0.07" spread="0.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.421"/>
                    <measurement group_id="O2" value="0.39" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.505"/>
                    <measurement group_id="O2" value="-0.14" spread="0.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-3.536</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.466</ci_lower_limit>
            <ci_upper_limit>-2.606</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean difference (24M DFS FU)</param_type>
            <param_value>-0.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.942</ci_lower_limit>
            <ci_upper_limit>0.738</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.690</ci_lower_limit>
            <ci_upper_limit>1.155</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.959</ci_lower_limit>
            <ci_upper_limit>1.122</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>0.412</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.887</ci_lower_limit>
            <ci_upper_limit>1.712</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Disease-related Symptoms-physical (DRS-P) Domain Score</title>
        <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-P domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to 12 questions (&quot;I have a lack of energy,&quot; &quot;I feel pain,&quot; for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 48). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Disease-related Symptoms-physical (DRS-P) Domain Score</title>
          <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-P domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to 12 questions (&quot;I have a lack of energy,&quot; &quot;I feel pain,&quot; for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 48). A negative mean indicates a worsening of condition.</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="559"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="0.235"/>
                    <measurement group_id="O2" value="-0.51" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="467"/>
                    <count group_id="O2" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.232"/>
                    <measurement group_id="O2" value="-0.25" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.247"/>
                    <measurement group_id="O2" value="-0.45" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.270"/>
                    <measurement group_id="O2" value="-0.19" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.329"/>
                    <measurement group_id="O2" value="-0.68" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-1.515</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.078</ci_lower_limit>
            <ci_upper_limit>-0.952</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU)</param_type>
            <param_value>0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.534</ci_lower_limit>
            <ci_upper_limit>0.561</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.888</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.555</ci_lower_limit>
            <ci_upper_limit>0.641</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.858</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>-0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.736</ci_lower_limit>
            <ci_upper_limit>0.614</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.300</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>0.452</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.404</ci_lower_limit>
            <ci_upper_limit>1.309</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Disease-related Symptoms-emotional (DRS-E) Domain Score</title>
        <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-E domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to the question of &quot;I worry that my condition will get worse&quot; by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 4).A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Disease-related Symptoms-emotional (DRS-E) Domain Score</title>
          <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The DRS-E domain assesses symptoms experienced in the past 7 days. Participants are asked to respond to the question of &quot;I worry that my condition will get worse&quot; by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 4).A negative mean indicates a worsening of condition.</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.045"/>
                    <measurement group_id="O2" value="0.14" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="465"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.048"/>
                    <measurement group_id="O2" value="0.19" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.050"/>
                    <measurement group_id="O2" value="0.15" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.059"/>
                    <measurement group_id="O2" value="0.20" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.065"/>
                    <measurement group_id="O2" value="0.17" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52)</param_type>
            <param_value>-0.103</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.211</ci_lower_limit>
            <ci_upper_limit>0.004</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.487</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU)</param_type>
            <param_value>-0.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.155</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.085</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.676</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>-0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.183</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.859</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>-0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.183</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Treatment Side Effects (TSE) Domain Score</title>
        <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The TSE domain assesses side effects experienced in the past 7 days. Participants are asked to respond to 3 questions (&quot;I have nausea,&quot; &quot;I have diarrhea,&quot; and &quot;I am bothered by side effects of treatment&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Treatment Side Effects (TSE) Domain Score</title>
          <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The TSE domain assesses side effects experienced in the past 7 days. Participants are asked to respond to 3 questions (&quot;I have nausea,&quot; &quot;I have diarrhea,&quot; and &quot;I am bothered by side effects of treatment&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="557"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="0.089"/>
                    <measurement group_id="O2" value="-0.33" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="465"/>
                    <count group_id="O2" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.052"/>
                    <measurement group_id="O2" value="0.04" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.057"/>
                    <measurement group_id="O2" value="-0.02" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.065"/>
                    <measurement group_id="O2" value="-0.00" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.074"/>
                    <measurement group_id="O2" value="0.03" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Diffeence (Week 52)</param_type>
            <param_value>-1.535</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.769</ci_lower_limit>
            <ci_upper_limit>-1.300</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Diffeence (24M DFS FU)</param_type>
            <param_value>0.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.202</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Diffeence (36M DFS FU)</param_type>
            <param_value>0.123</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.544</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Diffeence (48M DFS FU)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.110</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.518</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.124</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Functional Well Being (FWB) Domain Score</title>
        <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The FWB domain assesses well being in the past 7 days. Participants are asked to respond to 3 questions (&quot;I am able to work,&quot; &quot;I am able to enjoy life,&quot; and &quot;I am content with the quality of my life now&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using National Comprehensive Cancer Network (NCCN)/FACT FKSI-19 Scale Functional Well Being (FWB) Domain Score</title>
          <description>Health outcome and quality of life measured by NCCN/FACT FKSI-19 questionnaire for ITT ALL. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains. The FWB domain assesses well being in the past 7 days. Participants are asked to respond to 3 questions (&quot;I am able to work,&quot; &quot;I am able to enjoy life,&quot; and &quot;I am content with the quality of my life now&quot;) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total domain score of 0 to 12). A negative mean indicates a worsening of condition.</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="559"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.134"/>
                    <measurement group_id="O2" value="0.30" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="467"/>
                    <count group_id="O2" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.147"/>
                    <measurement group_id="O2" value="0.41" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.151"/>
                    <measurement group_id="O2" value="0.29" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.179"/>
                    <measurement group_id="O2" value="0.38" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.206"/>
                    <measurement group_id="O2" value="0.44" spread="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Diffeence (Week 52)</param_type>
            <param_value>-0.374</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.695</ci_lower_limit>
            <ci_upper_limit>-0.053</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Diffeence (24M DFS FU)</param_type>
            <param_value>-0.104</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.462</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.706</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU)</param_type>
            <param_value>0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.302</ci_lower_limit>
            <ci_upper_limit>0.446</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.612</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU)</param_type>
            <param_value>0.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.343</ci_lower_limit>
            <ci_upper_limit>0.583</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.870</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU)</param_type>
            <param_value>-0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.587</ci_lower_limit>
            <ci_upper_limit>0.496</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using EuroQoL-5D (EQ-5D) Score</title>
        <description>Health outcome and quality of life measured by using EQ-5D thermometer score and EQ-5D utility index (UI) score. The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>Week 52, 24M DFS FU, 36M DFS FU, 48M DFS FU, 54M DFS FU</time_frame>
        <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT All - Pazopanib</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
          </group>
          <group group_id="O2">
            <title>ITT All - Placebo</title>
            <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) With Pazopanib vs. Placebo for ITT ALL Assessed Using EuroQoL-5D (EQ-5D) Score</title>
          <description>Health outcome and quality of life measured by using EQ-5D thermometer score and EQ-5D utility index (UI) score. The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>Total (ITT All) included all randomized subjects, i.e. subjects either with a scheduled initial dose of 600 or 800 mg daily.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="769"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 thermo.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.744" spread="0.733"/>
                    <measurement group_id="O2" value="2.859" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU thermo.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.043" spread="0.741"/>
                    <measurement group_id="O2" value="4.296" spread="0.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU thermo.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.997" spread="0.774"/>
                    <measurement group_id="O2" value="3.150" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU thermo.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.683" spread="0.863"/>
                    <measurement group_id="O2" value="4.552" spread="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU thermos.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.650" spread="1.028"/>
                    <measurement group_id="O2" value="3.249" spread="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="571"/>
                    <count group_id="O2" value="548"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.008"/>
                    <measurement group_id="O2" value="0.003" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="460"/>
                    <count group_id="O2" value="453"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.008"/>
                    <measurement group_id="O2" value="0.017" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="404"/>
                    <count group_id="O2" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.009"/>
                    <measurement group_id="O2" value="-0.004" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.010"/>
                    <measurement group_id="O2" value="0.010" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54M DFS FU UI score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.012"/>
                    <measurement group_id="O2" value="0.003" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52 - thermo.)</param_type>
            <param_value>-2.116</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.872</ci_lower_limit>
            <ci_upper_limit>-0.359</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.778</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU - thermo)</param_type>
            <param_value>-0.253</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.014</ci_lower_limit>
            <ci_upper_limit>1.508</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU - thermo)</param_type>
            <param_value>0.847</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.030</ci_lower_limit>
            <ci_upper_limit>2.724</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.905</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU - thermo)</param_type>
            <param_value>0.131</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.032</ci_lower_limit>
            <ci_upper_limit>2.294</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.768</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU - thermo)</param_type>
            <param_value>0.401</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.269</ci_lower_limit>
            <ci_upper_limit>3.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (Week 52 - UI)</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>-0.007</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.130</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (24M DFS FU - UI)</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.005</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.520</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (36M DFS FU - UI)</param_type>
            <param_value>0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.030</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.276</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (48M DFS FU - UI)</param_type>
            <param_value>-0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.011</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.665</p_value>
            <method>analysis of covariance</method>
            <method_desc>adjusted for baseline score using mixed-model</method_desc>
            <param_type>Mean Difference (54M DFS FU - UI)</param_type>
            <param_value>-0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All Collected Deaths</title>
        <description>On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of approx. 13 months (treatment duration ranged from 0 to to 13 months). Deaths post treatment survival follow up were collected after the on-treatment period, up to approx. 8.5 years. Participants who had not died after study drug discontinuation were censored: 82% of participants in the ITT 600 population and 78% of participants in the ITT 800 population.</description>
        <time_frame>approx. 13 months, approx. 8.5 years</time_frame>
        <population>Safety 800: subjects who received at least one dose of study treatment in the ITT 800 population Safety 600: subjects who received at least one dose of study treatment in the ITT 600 population</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Pazopanib 800 mg</title>
            <description>Pazopanib 800 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Safety Placebo 800 mg</title>
            <description>Placebo matching pazopanib 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Safety Pazopanib 600 mg</title>
            <description>Pazopanib 600 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Safety Placebo 600 mg</title>
            <description>Placebo matching pazopanib 600 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>All Collected Deaths</title>
          <description>On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of approx. 13 months (treatment duration ranged from 0 to to 13 months). Deaths post treatment survival follow up were collected after the on-treatment period, up to approx. 8.5 years. Participants who had not died after study drug discontinuation were censored: 82% of participants in the ITT 600 population and 78% of participants in the ITT 800 population.</description>
          <population>Safety 800: subjects who received at least one dose of study treatment in the ITT 800 population Safety 600: subjects who received at least one dose of study treatment in the ITT 600 population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="568"/>
                <count group_id="O4" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-Treatment Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths post-treatment survival follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of approx. 13 months (treatment duration ranged from 0 to to 13 months).</time_frame>
      <desc>Adverse Event: Any sign or symptom that occurs during the study treatment plus up to 28 days post treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>ITT Pazopanib 800 mg</title>
          <description>Pazopanib 800 mg daily dose based on safety evaluation. Complete treatment is 12 months.</description>
        </group>
        <group group_id="E2">
          <title>ITT Placebo 800 mg</title>
          <description>Placebo matching pazopanib 800 mg daily. Complete treatment is 12 months.</description>
        </group>
        <group group_id="E3">
          <title>I TT Pazopanib 600 mg</title>
          <description>Pazopanib 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months.</description>
        </group>
        <group group_id="E4">
          <title>ITT Placebo 600 mg</title>
          <description>Placebo matching pazopanib 600 mg daily. Complete treatment is 12 months.</description>
        </group>
        <group group_id="E5">
          <title>ITT All - Pazopanib</title>
          <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily pazopanib.</description>
        </group>
        <group group_id="E6">
          <title>ITT All - Placebo</title>
          <description>All randomized subjects with a scheduled initial dose of 600 or 800 mg daily placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="167" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="68" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Lung transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Biliary neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Tumour thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="541" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="448" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="735" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="595" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="79" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="112" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="361" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="490" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="187" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="226" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="315" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="117" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="78" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="132" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="103" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="65" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="222" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="296" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="197" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="146" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="197" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="177" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="154" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="93" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="69" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="214" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="197" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="113" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="232" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="322" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="145" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="58" subjects_at_risk="762"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="294" subjects_at_risk="568"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="402" subjects_at_risk="766"/>
                <counts group_id="E6" subjects_affected="137" subjects_at_risk="762"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

